GlassScriptPhysician profile
Ann C Schweitzer
NPI 1598759797
$1,971.94
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Medical-Surgical (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $585 · 2022: $717 · 2023: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $603.31 | 2021-2023 | Trelegy Ellipta, Nucala, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.47 | 2021-2023 | Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $210.07 | 2021-2023 | Breztri, Tezspire |
| Grifols USA, LLC | $186.71 | 2021-2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $177.93 | 2021-2023 | Yupelri |
| United Therapeutics Corporation | $155.79 | 2021-2023 | Tyvaso, Orenitram |
| Genzyme Corporation | $69.60 | 2023 | |
| Philips North America LLC | $63.25 | 2021-2022 | |
| Advanced Respiratory, INC | $35.61 | 2021 | |
| Inogen, INC. | $20.22 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.01 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.82 | 2021 | |
| Pulmonx Corporation | $15.58 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Electromed, INC. | $15.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Schweitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.